thiophenes has been researched along with Brain Ischemia in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.51) | 18.7374 |
| 1990's | 6 (12.77) | 18.2507 |
| 2000's | 16 (34.04) | 29.6817 |
| 2010's | 21 (44.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennion, DM; Dang, AN; Domenig, O; Graham, JT; Isenberg, J; Jones, CH; Lindblad, L; Poglitsch, M; Steckelings, UM; Sumners, C; Waters, MF | 1 |
| Anticoli, S; Dalmaso, SG; Marchitto, N; Pannozzi, A; Raimondi, G; Sindona, F | 1 |
| Boujon, V; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Uhlemann, R; Wegner, S; Wright, MB | 1 |
| Heitmeier, S; Jenetzky, E; Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Bennion, DM; Desland, F; Joseph, JP; Katovich, MJ; Mecca, AP; Patel, NA; Pioquinto, DJ; Regenhardt, RW; Rodríguez, V; Steckelings, UM; Sumners, C; Unger, T | 1 |
| Brouns, R; De Keyser, J; De Smedt, A; Jochmans, K; Nieboer, K; van Hooff, RJ; Yperzeele, L | 1 |
| Foley, J; Kirchhof, P; Lip, GY | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Kurata, T; Omote, Y; Sato, K; Yamashita, T; Yunoki, T | 1 |
| Fukae, J; Higashi, T; Inoue, T; Iwaasa, M; Kimura, S; Ogata, T; Okawa, M; Tsuboi, Y | 1 |
| Lamichhane, D | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Hashi, S; Penge, J; Simister, R | 1 |
| Bambakidis, NC; Barnett, A; Filichia, E; Jin, Y; Luo, Y; Raviv, N | 1 |
| Bari, F; Farkas, E; Hertelendy, P; Ivánkovits-Kiss, O; Menyhárt, Á; Puskás, T; Tóth, R; Varga, DP; Zölei-Szénási, D | 1 |
| Brown, DA; Chang, FL; Curfman, ET; Kuo, PC; Paraiso, HC; Scofield, BA; Yen, JH; Yu, IC | 1 |
| Baik, EJ; Jung, YS; Kim, YS; Lee, BK; Lee, DH; Lee, KH; Lee, MG; Lee, S; Lee, SH; Moon, CH; Park, S; Park, SL; Yi, KY; Yoo, SE; Yoon, JS | 1 |
| Rosenberg, GA; Walker, EJ | 1 |
| Faxon, DP; Freedman, JE | 1 |
| Bobrova, MV; Listopadov, IuI; Rzheusskaia, GV; Umrudina, AG | 1 |
| Hasegawa, Y; Rolland, W; Sozen, T; Suzuki, H; Zhang, JH | 1 |
| Easton, JD | 1 |
| Antman, EM; Braunwald, E; Desai, N; Murphy, SA; Musumeci, G; Ragosta, M; Wiviott, SD | 1 |
| Ji, H; Lai, Y; Li, T; Ling, J; Liu, J; Peng, S; Tian, J; Wang, X; Wu, J; Zhang, Y | 1 |
| Lipták, J | 1 |
| Grove, EL; Husted, SE; Kraglund, KL; Modrau, B | 1 |
| Baronti, R; Calvani, M; Camaioni, E; Chiarugi, A; Costantino, G; Marinozzi, M; Meli, E; Moroni, F; Pellegrini-Giampietro, DE; Pellicciari, R; Picca, R | 1 |
| Pfefferkorn, T; Rosenberg, GA | 1 |
| foniakin, AV; Geraskina, LA; Konradi, VV; Sharypova, TN; Suslina, ZA | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Mirouze, J | 1 |
| Herce Muñoz, M | 1 |
| López-Trigo Picho, J; Sancho Rieger, J | 1 |
| Elben, U; Grome, JJ; Lee, GE; Lee, TB; Martin, LL; Paulus, E; Porsche-Wiebking, E; Rudolphi, KA; Rush, DK; Wilmot, CA | 1 |
| Cao, X; Phillis, JW | 1 |
| Gidday, JM; Halle, JN; Kasper, CE; Koos, BJ | 1 |
| Auguet, M; Chabrier, PE; Demerlé-Pallardy, C | 1 |
| Dawson, VL | 1 |
| Auguet, M; Chabrier, PE; Cornet, S; Demerlé-Pallardy, C; Marin, JG; Spinnewyn, B | 1 |
| Cregan, E; Macdonald, JE; McCarthy, DJ; Reif, DW | 1 |
| Hurn, PD; Murphy, SJ; Rossberg, MI; Traystman, RJ | 1 |
| Asahi, K; Asahi, M; del Zoppo, GJ; Fini, ME; Jung, JC; Lo, EH | 1 |
| Ago, T; Fujishima, M; Ibayashi, S; Kitayama, J; Kitazono, T; Ooboshi, H; Takaba, H; Yao, H | 1 |
| Lo, EH; Sumii, T | 1 |
| Berezov, VP; Boĭko, AN; Gusev, EI; Martynov, MIu; Maskarov, AN; Petukhov, EB | 1 |
| Attucci, S; Cozzi, A; Meli, E; Moroni, F; Noe, C; Pellegrini-Giampietro, DE; Pellicciari, R; Picca, R; Sarichelou, I; Scheideler, MA | 1 |
| Obermeier, K; Thiemer, K; von Schlichtegroll, A | 1 |
| Chernack, J; Cornfeldt, ML; Fielding, S; Martin, LL; Payack, JF; Ramirez, V; Rudolphi, KA; Rush, DK; Wilker, JC; Wilmot, CA | 1 |
7 review(s) available for thiophenes and Brain Ischemia
| Article | Year |
|---|---|
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
Update on secondary prevention of ischaemic stroke.
Topics: Anticoagulants; Blood Coagulation; Brain Ischemia; Foramen Ovale, Patent; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Ventricular Dysfunction, Left | 2014 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2013 |
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
Nitric oxide synthases: targets for therapeutic strategies in neurological diseases.
Topics: Alzheimer Disease; Amidines; Amyotrophic Lateral Sclerosis; Animals; Benzylamines; Brain Injuries; Brain Ischemia; Enzyme Induction; Humans; Huntington Disease; Mice; Mice, Neurologic Mutants; Mice, Transgenic; Nerve Degeneration; Nerve Tissue Proteins; Nervous System Diseases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Organ Specificity; Polymethacrylic Acids; Pyrazines; Thiophenes | 1999 |
Potent neuroprotectants linked to bifunctional inhibition.
Topics: Animals; Brain; Brain Ischemia; Enzyme Inhibitors; Free Radical Scavengers; Mice; Models, Biological; Neuroprotective Agents; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Pyrazines; Rats; Thiophenes | 1999 |
3 trial(s) available for thiophenes and Brain Ischemia
| Article | Year |
|---|---|
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
Topics: Acute Coronary Syndrome; Aged; Brain Ischemia; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Treatment Outcome; United States | 2011 |
Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Clinical Trials as Topic; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Electrocardiography; Fluorescein Angiography; Follow-Up Studies; Humans; Middle Aged; Patient Compliance; Platelet Aggregation; Thiophenes; Ticlopidine | 1984 |
37 other study(ies) available for thiophenes and Brain Ischemia
| Article | Year |
|---|---|
Protective effects of the angiotensin II AT
Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Drug Administration Routes; Drug Delivery Systems; Humans; Male; Nasal Mucosa; Neuroprotective Agents; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes | 2018 |
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Female; Geriatric Assessment; Hospitalization; Humans; Inpatients; Male; Movement; Parkinson Disease, Secondary; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sampling Studies; Severity of Illness Index; Stroke; Tetrahydronaphthalenes; Thiophenes; Time Perception; Transdermal Patch; Treatment Outcome | 2019 |
Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Mice; Oxazoles; PPAR alpha; PPAR gamma; Stroke; Thiophenes | 2019 |
Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
Topics: Animals; Anticoagulants; Blood-Brain Barrier; Brain Ischemia; Cerebral Hemorrhage; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Time Factors | 2014 |
The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Brain Infarction; Brain Ischemia; CD11b Antigen; Cerebrovascular Circulation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Glial Fibrillary Acidic Protein; Imidazoles; Male; Nitric Oxide Synthase Type II; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Stroke; Sulfonamides; Thiophenes; Time Factors | 2014 |
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.
Topics: Aged, 80 and over; Brain Ischemia; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Morpholines; Polypharmacy; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
Topics: Animals; Anticoagulants; Blood Coagulation; Brain; Brain Ischemia; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Morpholines; Pyrazoles; Pyridones; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator | 2014 |
Revascularization for acute ischemic stroke is safe for rivaroxaban users.
Topics: Aged, 80 and over; Brain Ischemia; Cerebral Revascularization; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombectomy; Tissue Plasminogen Activator | 2014 |
Successful intravenous thrombolysis following full dose rivaroxaban 5 hours before ictus.
Topics: Administration, Oral; Atrial Fibrillation; Brain Ischemia; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Morpholines; Rivaroxaban; Severity of Illness Index; Thiophenes; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator | 2015 |
The shh signaling pathway is upregulated in multiple cell types in cortical ischemia and influences the outcome of stroke in an animal model.
Topics: Animals; Behavior, Animal; Brain Ischemia; Cerebral Cortex; Cyclohexylamines; Hedgehog Proteins; Male; Mice; Signal Transduction; Stroke; Tamoxifen; Thiophenes | 2015 |
Contribution of prostanoid signaling to the evolution of spreading depolarization and the associated cerebral blood flow response.
Topics: Animals; Brain; Brain Ischemia; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Laser-Doppler Flowmetry; Male; Nitrobenzenes; Prosencephalon; Prostaglandins; Pyrazoles; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfonamides; Thiophenes; Triazoles | 2016 |
3H-1,2-Dithiole-3-thione as a novel therapeutic agent for the treatment of ischemic stroke through Nrf2 defense pathway.
Topics: Animals; Antioxidants; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Mice; NF-E2-Related Factor 2; Reactive Oxygen Species; Signal Transduction; Stroke; Thiones; Thiophenes | 2017 |
Effects of KR-33028, a novel Na+/H+ exchanger-1 inhibitor, on glutamate-induced neuronal cell death and ischemia-induced cerebral infarct.
Topics: Animals; Apoptosis; Brain Ischemia; Caspase 3; Cells, Cultured; Cerebral Cortex; Cerebral Infarction; Enzyme Activation; Glutamic Acid; Guanidines; In Situ Nick-End Labeling; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Necrosis; Neurons; Neuroprotective Agents; Pyrazoles; Rats; Rats, Sprague-Dawley; Sodium-Hydrogen Exchangers; Thiophenes | 2009 |
TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Encephalitis; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gliosis; Hippocampus; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Degeneration; Neuroprotective Agents; Phenylalanine; Receptors, Tumor Necrosis Factor, Type I; Reperfusion Injury; Thiophenes; Tissue Inhibitor of Metalloproteinase-3; Tumor Necrosis Factor-alpha | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
[Cymbalta (duloxetine) in the treatment of anxiety-depressive disorders in patients with discirculatory encephalopathy].
Topics: Adult; Aged; Antidepressive Agents; Anxiety Disorders; Brain Ischemia; Depressive Disorder; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychological Tests; Selective Serotonin Reuptake Inhibitors; Syndrome; Thiophenes; Treatment Outcome | 2009 |
Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Fingolimod Hydrochloride; Immunosuppressive Agents; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Nerve Degeneration; Neuroprotective Agents; Oxadiazoles; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Stroke; Thiophenes; Treatment Outcome | 2010 |
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Free Radical Scavengers; Male; Neuroprotective Agents; PC12 Cells; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Stereoisomerism; Stroke; Structure-Activity Relationship; Thiophenes | 2012 |
[Rivaroxaban versus warfarin: results of the ROCKET study].
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Humans; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia.
Topics: Animals; Brain Ischemia; Cells, Cultured; Disease Models, Animal; Isoquinolines; Mice; Neuroprotective Agents; Phenanthrenes; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Thiophenes | 2003 |
Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Infarction, Middle Cerebral Artery; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Phenylalanine; Rats; Rats, Wistar; Recombinant Proteins; Reperfusion; Sucrose; Survival Rate; Thiophenes; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Water | 2003 |
[Cerebral hemodynamics and endothelium function in patients with cerebrovascular pathology treated by teveten].
Topics: Acrylates; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Brain; Brain Ischemia; Endothelium, Vascular; Female; Hemodynamics; Humans; Imidazoles; Male; Middle Aged; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
[Ticlopidine in the prevention of recurrent cerebral ischemic accidents].
Topics: Anticoagulants; Brain Ischemia; Humans; Recurrence; Thiophenes; Ticlopidine | 1984 |
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Rectum; Recurrence; Thiophenes; Ticlopidine | 1984 |
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
Topics: Aniline Compounds; Animals; Anti-Anxiety Agents; Anticonvulsants; Binding, Competitive; Brain Ischemia; Cerebral Infarction; Crystallography, X-Ray; Disease Models, Animal; Gerbillinae; Hippocampus; Isomerism; Male; Mice; Molecular Structure; N-Methylaspartate; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Thiophenes | 1994 |
Adenosine A1 receptor enhancer, PD 81,723, and cerebral ischemia/reperfusion injury in the gerbil.
Topics: Animals; Brain Ischemia; Gerbillinae; Male; Receptors, Purinergic P1; Reperfusion Injury; Thiophenes | 1995 |
Enhancing adenosine A1 receptor binding reduces hypoxic-ischemic brain injury in newborn rats.
Topics: Animals; Animals, Newborn; Brain Injuries; Brain Ischemia; Hypoxia; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Thiophenes | 1997 |
BN 80933 inhibits F2-isoprostane elevation in focal cerebral ischaemia and hypoxic neuronal cultures.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Culture Media, Conditioned; Dinoprost; Enzyme Inhibitors; F2-Isoprostanes; Hypoxia, Brain; Infarction, Middle Cerebral Artery; L-Lactate Dehydrogenase; Neuroprotective Agents; Pyrazines; Rats; Rats, Wistar; Reperfusion Injury; Thiophenes | 2000 |
Discovery and development of neuronal nitric oxide synthase inhibitors.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dogs; Drug Design; Enzyme Inhibitors; Humans; Isoquinolines; Kinetics; Macaca fascicularis; Male; Mice; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Rats; Stroke; Tetrahydroisoquinolines; Thiophenes | 2000 |
LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Carbon Radioisotopes; Cerebral Infarction; Cerebrovascular Circulation; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Ovariectomy; Piperidines; Rats; Rats, Wistar; Receptors, Estrogen; Thiophenes | 2000 |
Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.
Topics: Animals; Brain; Brain Ischemia; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Phenylalanine; Protease Inhibitors; Stroke; Thiophenes; Transcription, Genetic | 2000 |
Inhibition of Na+/H+ exchanger reduces infarct volume of focal cerebral ischemia in rats.
Topics: Animals; Brain Ischemia; Calcium; Cell Death; Cerebral Cortex; Cerebral Infarction; Cerebrovascular Circulation; Disease Models, Animal; Enzyme Inhibitors; Guanidines; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Rats; Rats, Inbred SHR; Sodium; Sodium-Hydrogen Exchangers; Thiophenes; Treatment Outcome | 2001 |
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.
Topics: Animals; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Circulation; Disease Models, Animal; Enzyme Inhibitors; Intracranial Embolism; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Phenylalanine; Rats; Rats, Inbred SHR; Sodium, Dietary; Survival Rate; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator | 2002 |
[Eprosartan mesylate in controlling of blood pressure in patients with ischemic stroke].
Topics: Aged; Antihypertensive Agents; Brain; Brain Ischemia; Cerebrovascular Circulation; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Thiophenes | 2002 |
The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death.
Topics: Animals; Brain Ischemia; Cell Death; Cell Hypoxia; Cells, Cultured; Cricetinae; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Hippocampus; Infarction, Middle Cerebral Artery; Mice; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Thiophenes | 2002 |
[The influence of tinofedrine on cerebral energy metabolism in normotensive, hypotensive and hypoxemic rats after carotis ligation (author's transl)].
Topics: Animals; Benzyl Alcohols; Benzyl Compounds; Brain; Brain Ischemia; Carotid Arteries; Energy Metabolism; Hypotension; Male; Rats; Thiophenes; Time Factors | 1978 |
Preclinical anticonvulsant and neuroprotective profile of 8319, a non-competitive NMDA antagonist.
Topics: Aniline Compounds; Animals; Anticonvulsants; Binding, Competitive; Brain Diseases; Brain Ischemia; Dizocilpine Maleate; Gerbillinae; Hippocampus; Male; Mice; Mice, Inbred Strains; N-Methylaspartate; Rats; Rats, Inbred Strains; Thiophenes; Tritium | 1990 |